Adicet Bio, Inc. (ACET) Expected to Beat Earnings Estimates: Should You Buy?Zacks Investment Research • 03/03/22
Adicet Bio, Inc. Announces Closing of $100 Million Public Follow-On Offering and Exercise in Full of the Underwriters' Option to Purchase Additional SharesGlobeNewsWire • 12/10/21
Adicet Bio Raises $87M Via Equity To Fund Development Of Non-Hodgkin's Lymphoma CandidateBenzinga • 12/08/21
Adicet Stock Rallies After Early Responses For Off-The-Shelf Drug In B-cell Non-Hodgkin's LymphomaBenzinga • 12/06/21
Adicet Bio Announces Positive Interim Clinical Data From First-Ever Allogeneic, Off-The-Shelf, Gamma Delta CAR T Investigational Cell TherapyGlobeNewsWire • 12/06/21
Adicet Bio to Host Webcast Presentation of ADI-001 Interim Clinical Data in B Cell Non-Hodgkin's LymphomaGlobeNewsWire • 11/29/21
Adicet Announces Appointment of Dr. Michael G. Kauffman to the Board of DirectorsGlobeNewsWire • 11/18/21
Adicet Presents Preclinical Data for ADI-002, a GPC3-Targeted Development Candidate for Solid Tumors, at the SITC Annual MeetingGlobeNewsWire • 11/12/21
Adicet Reports Third Quarter 2021 Financial Results and Provides Business UpdatesGlobeNewsWire • 11/10/21
Adicet Announces Trials in Progress Poster Presentation for ADI-001 at 2021 ASH Annual MeetingGlobeNewsWire • 11/04/21
Adicet to Present Preclinical Data from Allogeneic Gamma Delta T Cell Platform at SITC 36th Annual MeetingGlobeNewsWire • 10/04/21
Twist Bioscience Collaborates with Adicet Bio to Accelerate Discovery of Gamma Delta T Cell Cancer TherapeuticsBusiness Wire • 09/13/21